Biontech Se ADR (BNTX) Stock Price, Quote & News

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 6131 9084

Fax: 49 6131 9084

Website: www.biontech.de

Address:

An der Goldgrube 12, Mainz, Germany

Pillemann1 Aug. 8 at 3:22 PM

$BNTX I totally agree. But if so it will sky-rocket if not to orbit.

0 · Reply

taxplanr Aug. 8 at 11:28 AM

The vaccine schedule and nursing homes are the only sales channels for the bioweapons industry $PFE $BNTX $MRNA Fauci and Gates are the most hated on the planet https://www.zerohedge.com/political/what-else-are-they-hiding

1 · Reply

Kosmokrat Aug. 8 at 10:29 AM

$BNTX The real trigger for any SP movement will be the upcoming data readouts for the phase 3 studies for BNT111 & BNT122, and the BLA filing for BNT323.

1 · Reply

Samishere Aug. 8 at 3:30 AM

$BNTX

0 · Reply

Samishere Aug. 7 at 5:06 PM

$BNTX

0 · Reply

AIIAAIIA_88 Aug. 7 at 2:50 PM

$BNTX Heavier volume than usual. Something coming up next week? I hope that this breaks into triple digits soon. JMO

0 · Reply

TICKERTUTOR Aug. 6 at 8:36 PM

$PFE $BNTX $MRNA THE TRUMP ADMINISTRATION IS WEIGHING AN ORDER ON AUTISM AND VACCINES

1 · Reply

TimothyGonzales403 Aug. 6 at 3:31 AM

$CSIQ $CAKE $CTRI $BNTX $AHCO Canadian Solar benefits from renewable energy demand, Cheesecake Factory generates dependable restaurant cash flow, CTRI remains speculative, BioNTech advances oncology therapies, and AdaptHealth expands home healthcare services.

1 · Reply

Samishere Aug. 5 at 4:38 PM

$BNTX

0 · Reply

Estimize Aug. 5 at 10:01 AM

Wall St is expecting 0.86 EPS for $BNTX Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_co

0 · Reply

BioNTech price target lowered to $130 from $135 at Evercore ISI

2026-08-05T11:05:37.000Z - 3 days ago

BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T10:35:32.000Z - 3 days ago

BioNTech price target lowered to $125 from $130 at Citi

Aug 4, 2026, 8:00 AM EDT - 4 days ago

BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 4 days ago

BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 4 days ago

BioNTech SE Slides: Q2 2026

Aug 4, 2026, 7:12 AM EDT - 4 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

PFE

Aug 4, 2026, 7:02 AM EDT - 4 days ago

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

2026-08-04T10:50:25.000Z - 4 days ago

BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B

Aug 4, 2026, 6:45 AM EDT - 4 days ago

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Aug 3, 2026, 5:29 AM EDT - 5 days ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO

2026-08-03T09:05:08.000Z - 5 days ago

BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed

Aug 3, 2026, 5:00 AM EDT - 5 days ago

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

2026-07-29T20:42:19.000Z - 10 days ago

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

PFE

Jul 29, 2026, 4:30 PM EDT - 10 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

PFE

Jul 21, 2026, 6:45 AM EDT - 18 days ago

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

2026-07-08T11:40:53.000Z - 4 weeks ago

BioNTech price target lowered to $119 from $126 at Morgan Stanley

Jul 3, 2026, 1:51 AM EDT - 5 weeks ago

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Jun 17, 2026, 2:38 AM EDT - 7 weeks ago

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

MRNA

2026-05-31T21:45:07.000Z - 2 months ago

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial

BMY

May 30, 2026, 2:15 PM EDT - 2 months ago

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 27, 2026, 11:07 AM EDT - 2 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch

2026-05-27T08:45:10.000Z - 2 months ago

BioNTech upgraded to Buy from Neutral at UBS

May 22, 2026, 5:00 AM EDT - 2 months ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

2026-05-21T21:20:11.000Z - 2 months ago

Bernstein starts BioNTech at Market Perform, sees high registration risk

2026-05-21T20:27:55.000Z - 2 months ago

BioNTech initiated with a Market Perform at Bernstein

May 15, 2026, 4:15 PM EDT - 3 months ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Transcript: AGM 2026

May 7, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces New ADS Repurchase Program

May 6, 2026, 7:44 AM EDT - 3 months ago

Germany says vaccine supply secure despite BioNTech production loss

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

BioNTech SE Slides: Q1 2026

May 5, 2026, 7:26 AM EDT - 3 months ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

May 5, 2026, 6:47 AM EDT - 3 months ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:45 AM EDT - 3 months ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Apr 21, 2026, 5:35 PM EDT - 3 months ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

Apr 21, 2026, 6:45 AM EDT - 3 months ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

Apr 11, 2026, 7:00 AM EDT - 4 months ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 1, 2026, 11:39 AM EDT - 4 months ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

Mar 24, 2026, 6:45 AM EDT - 4 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 10, 2026, 2:48 PM EDT - 5 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 1:29 PM EDT - 5 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 7:40 AM EDT - 5 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:18 AM EDT - 5 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 6:50 AM EDT - 5 months ago

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:49 AM EDT - 5 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:45 AM EDT - 5 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:33 AM EDT - 5 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Feb 24, 2026, 6:45 AM EST - 5 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 19, 2026, 1:25 PM EST - 6 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

Jan 28, 2026, 8:00 AM EST - 6 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 13, 2026, 5:15 PM EST - 7 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 7 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 10:00 AM EST - 7 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Dec 18, 2025, 4:45 AM EST - 8 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 9, 2025, 7:00 AM EST - 8 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

Dec 6, 2025, 3:30 PM EST - 8 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 3, 2025, 9:01 AM EST - 8 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

Dec 1, 2025, 3:50 PM EST - 8 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Dec 1, 2025, 12:35 PM EST - 8 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

Nov 26, 2025, 7:30 AM EST - 9 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 13, 2025, 5:20 PM EST - 9 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Nov 13, 2025, 8:17 AM EST - 9 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

Nov 11, 2025, 9:00 AM EST - 9 months ago

BioNTech SE Transcript: R&D Day

Nov 11, 2025, 9:00 AM EST - 9 months ago

BioNTech SE Slides: R&D Day

Nov 3, 2025, 8:00 AM EST - 9 months ago

BioNTech SE Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

BioNTech SE Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

BioNTech SE Slides: Q3 2025

Nov 3, 2025, 6:47 AM EST - 9 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:45 AM EST - 9 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 27, 2025, 7:45 AM EDT - 10 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 22, 2025, 6:45 AM EDT - 10 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Pillemann1 Aug. 8 at 3:22 PM

$BNTX I totally agree. But if so it will sky-rocket if not to orbit.

0 · Reply

taxplanr Aug. 8 at 11:28 AM

1 · Reply

Kosmokrat Aug. 8 at 10:29 AM

$BNTX The real trigger for any SP movement will be the upcoming data readouts for the phase 3 studies for BNT111 & BNT122, and the BLA filing for BNT323.

1 · Reply

Samishere Aug. 8 at 3:30 AM

$BNTX

0 · Reply

Samishere Aug. 7 at 5:06 PM

$BNTX

0 · Reply

AIIAAIIA_88 Aug. 7 at 2:50 PM

$BNTX Heavier volume than usual. Something coming up next week? I hope that this breaks into triple digits soon. JMO

0 · Reply

TICKERTUTOR Aug. 6 at 8:36 PM

$PFE $BNTX $MRNA THE TRUMP ADMINISTRATION IS WEIGHING AN ORDER ON AUTISM AND VACCINES

1 · Reply

TimothyGonzales403 Aug. 6 at 3:31 AM

1 · Reply

Samishere Aug. 5 at 4:38 PM

$BNTX

0 · Reply

Estimize Aug. 5 at 10:01 AM

Wall St is expecting 0.86 EPS for $BNTX Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/bntx?chart=historical&metric_name=eps&utm_co

0 · Reply

GenevieveCarrier146 Aug. 5 at 6:50 AM

$MKL $ULTA $DRI $IHG $BNTX Markel combines insurance with long-term investing, Ulta Beauty benefits from premium cosmetics demand, Darden Restaurants expands casual dining brands, InterContinental Hotels benefits from travel demand, and BioNTech advances oncology innovation.

0 · Reply

Samishere Aug. 5 at 1:22 AM

$BNTX

0 · Reply

Nitroxic73 Aug. 4 at 2:53 PM

$BNTX ridiculous earnings report. not a single reason given to own the stock

2 · Reply

tkstockpicker Aug. 4 at 1:38 PM

$BNTX I mean…LOL

2 · Reply

La_Parka3 Aug. 4 at 1:35 PM

$BNTX $MRNA $PFE "Vaccines are bioweapons."

2 · Reply

taxplanr Aug. 4 at 1:33 PM

Irrational bioweapon investor behavior explained $MRNA $BNTX $PFE https://www.instagram.com/p/DblbxywGAzV/?img_index=4&igsh=YXBkMmozaWhiM2lk

0 · Reply

IndyOne Aug. 4 at 1:19 PM

$BNTX ugly Q2 headline numbers: * €105.6M revenue, sharply down YoY * €820.8M net loss * Full‑year revenue guidance cut to €1.6B–€1.9B (down from €2.0B–€2.3B) * No leader until February 2027. CEO starting separate company. What technology will he take?. . . it will be negotiated with himself. No conflict of interest. LOL * Morgan Stanley asked about Moderna's program success on BNTX earnings call and if it gave confidence to future BNTX clinical results. Answer was no! Moderna is so much further ahead with efficacy numbers. Dead money, until early 2028 or late 2027.

0 · Reply

tkstockpicker Aug. 4 at 12:44 PM

$BNTX Probably holds 88 area

0 · Reply

OpenOutcrier Aug. 4 at 12:41 PM

$BNTX (-3.4% pre) BioNTech Non-GAAP EPS of -€2.22, revenue of €105.6M https://ooc.bz/l/109806

0 · Reply

BullYa Aug. 4 at 12:27 PM

$BNTX retest 📉…$80

0 · Reply

AdibRamadan Aug. 4 at 12:04 PM

$BNTX The latest results reinforce a familiar pattern: BioNTech continues to manage market expectations by leaning on post‑COVID profitability while signaling stability rather than innovation-driven momentum. Despite significant R&D allocation, the mRNA oncology platform has not produced meaningful clinical breakthroughs over the past three decades. For investors, the key consideration is the widening gap between innovation output and the remaining runway of cash flows — a dynamic that should be reflected in forward-looking valuation models.

0 · Reply

StocktwitsEarnings Aug. 4 at 11:44 AM

$BNTX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.24 down -102.50% YoY • Reported revenue of $145.8M down -44.10% YoY • BioNTech is revising its full-year 2026 revenue guidance to 1.61.9 billion, while maintaining adjusted SG&A expenses at 700800 million and adjusting R&D expense guidance to 2.02.3 billion for BioNTech.

1 · Reply

Market Cap	23.69B
Revenue (ttm)	3.25B
Net Income (ttm)	-1.29B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.59%
Debt to Equity Ratio	0.02

Volume	1,427,900
Avg Vol	980,824
Day's Range	N/A - N/A
Shares Out	252.88M
Stochastic %K	88%
Beta	1.27
Analysts	Strong Sell
Price Target	$124.00